Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
about
Arylesterase phenotype-specific positive association between arylesterase activity and cholinesterase specific activity in human serumDescriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysisNanopharmaceuticals (part 1): products on the market.The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?Strategies that delay or prevent the timely availability of affordable generic drugs in the United StatesMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Insoluble drug delivery strategies: review of recent advances and business prospects.
P2860
Q28397147-30551C7E-FCFF-4863-AC9A-82C4C4BC3048Q34014812-B2E9401A-6808-4AD1-9067-581ED2AB99CDQ34230175-21CD40E3-B809-43F4-8C1E-ACD2D77E47EEQ35671001-07DEECA2-BAEB-4C59-B156-32767D61BD86Q37026035-0D631937-5BE7-4F8B-A5A4-7D6896E5DBC2Q37254899-9EAEB16D-B0D9-470F-BCD2-5B6D00553C76Q38637003-C3DFCBBE-17EA-4B9B-9260-F4338B11DC8D
P2860
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
@en
type
label
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
@en
prefLabel
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
@en
P2093
P2860
P1476
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.
@en
P2093
Cynthia A Jackevicius
Joseph S Ross
Nicholas S Downing
P2860
P304
P356
10.1001/2013.JAMAINTERNMED.806
P407
P577
2012-05-01T00:00:00Z